GeoVax among ‘few companies’ developing vaccines for Ebola, says Noble Capital

Noting that the World Health Organization just declared Ebola a Public Health Emergency of International Concern, the highest level of global health alert it can issue, Noble Capital points out that GeoVax is “one of the few companies that has developed vaccines” against Mpox, Ebola, and other infectious diseases. The firm, which notes that GeoVax has completed pre-clinical work testing vaccines for hemorrhagic fever viruses, including Ebola, Sudan, and Marburg, says increased attention to Ebola could help obtain non-dilutive funding for these programs. The firm reiterates an Outperform rating and $10 price target on GeoVax shares.